Novavax COVID-19 vaccine is 89 percent effective, but much less so against South African strain
Novavax, a biotech firm based in Maryland, announced Thursday that its COVID-19 vaccine was 89.3 percent effective at protecting people from the disease in Britain, including against a new and more infectious strain now dominant in the U.K., but only 49 percent effective in a smaller trial in South Africa. More than 90 percent of the South African subjects who got sick were infected with the new strain, according to preliminary results. Novavax announced the interim results of its Phase 3 U.K. study and Phase 2 trial in South Africa in a press release.
Novavax's findings were a sobering signal that the current vaccines won't work as well against the new variants. The company's vaccine appeared to be 95.6 percent effective against the original strain of the coronavirus but 85.6 percent effective against the U.K. variant. Novavax also said its vaccine was 60 percent effective in its South African trial if you excluded the subgroup with HIV. It is already working on a modified version of its vaccine to specifically target the South African variant, which was first confirmed have hit the U.S. on Thursday.
The U.S. has approved COVID-19 vaccines from Pfizer/BioNTech and Moderna, and Johnson & Johnson is expected to release the findings of its Phase 3 trial sometime next week. Johnson & Johnson has been testing its vaccine in South Africa and Brazil, home to another new mutation, so health experts are hoping to get more clues about how current vaccines fare against the new strains.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Novavax said it has already started the process to seek regulatory approval for its vaccine in the U.K., and it could be approved in the U.S. as early as April, though the Food and Drug Administration might wait for the results of its ongoing Phase 3 trial in Mexico and the U.S. Public health officials would welcome any new supply of a safe and effective vaccine. The FDA has said vaccine candidates have to be at least 50 percent effective. The U.S. contributed $1.6 billion to Novavax's vaccine effort last year and has preordered 100 million doses.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Indie film's 'very brief' use of AI sparks backlash and calls for boycotts
Talking Points Did the creators of a new horror movie make a deal with the artificial intelligence devil?
By Rafi Schwartz, The Week US Published
-
Could Taylor Swift swing the election?
Today's Big Question The pop star has outsized influence — and that extends beyond the music industry
By Anya Jaremko-Greenwold Published
-
Kevin Hart awarded Mark Twain Prize
Speed Read He is the 25th recipient of the prestigious comedy prize
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published